Insights
Search Results
Alerts
8.06.26
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Alerts
7.29.26
Back-to-Back Executive Orders Shape the U.S. Quantum Agenda: What Founders and Investors Need to Know
On June 22, 2026, the administration issued two Executive Orders: Executive Order 14413, Ushering in the Next Frontier of Quantum Innovation (Quantum Innovation Executive Order) and Executive Order 14412, Securing the Nation Against Advanced Cryptographic Attacks (Post-Quantum Cryptography Executive Order). Together, the Executive Orders reinforce the federal government’s long-term commitment to quantum information science and technology (QIST) while continuing to frame quantum as both an economic and national security priority. Although they impose relatively few immediate legal obligations on most companies, the Executive Orders provide important signals about where federal investment, procurement, and strategic partnerships are likely to emerge over the coming years.
Client Highlights
7.21.26
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
11.04.25
Firm Advises Automation Anywhere on Acquisition of Aisera
On November 4, 2025, Automation Anywhere, the leading provider of Agentic Process Automation (APA) and agentic solutions, announced it has acquired Aisera, the leading provider of agentic solutions for autonomous IT. The acquisition expands Automation Anywhere’s deep AI portfolio and expertise in automating mission-critical enterprise processes with Aisera’s industry-leading self-service agents for IT Service Management (ITSM), HR, and Customer Service—creating the industry’s most comprehensive agentic automation portfolios to deliver autonomous operations across departments and improve employee and customer experience. Wilson Sonsini Goodrich & Rosati advised Automation Anywhere on the transaction.
Client Highlights
6.30.25
Wilson Sonsini Advises Portal Biotech on IP Matters Related to $35 Million Series A Financing
On June 30, 2025, Portal Biotech, a pioneering biotechnology company based in London, announced a $35 million Series A financing round—one of the largest investments in a life sciences tools company in Europe. The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with participation from existing investors Science Creates Venture Capital, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank, and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Portal Biotech on IP diligence matters related to the transaction.
Client Highlights
2.21.25
Wilson Sonsini Advises Anaerobe Systems on Acquisition by Biolog
On February 12, 2025, Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, announced the acquisition of Anaerobe Systems. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies. Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction.
Client Highlights
2.18.25
Wilson Sonsini Advises Esperto Medical on Oversubscribed Series A
On February 18, 2025, Esperto Medical™, a healthtech start-up specializing in critical care and remote patient monitoring, announced the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures. Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction.
Client Highlights
10.02.24
Wilson Sonsini Advises Pure Lithium on Asset Acquisition of Dimien
On October 1, 2024, Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announced the acquisition of all the assets of Dimien Inc., a private U.S. vanadium cathode materials company. Pure Lithium acquired Dimien’s intellectual property, know-how, and manufacturing equipment. Dimien's experienced team will also join the company. Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction.
Client Highlights
8.22.24
Firm Advises Novo Holdings on IP Matters Related to Oxford Nanopore Investment
On August 1, 2024, Novo Holdings, a leading international life science investor, announced a £50 million investment in Oxford Nanopore Technologies, a leading UK-listed company behind a new generation of molecular sensing technology based on nanopores, which is today used for DNA/RNA sequencing. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on IP diligence matters related to the transaction.
Client Highlights
5.29.24
Wilson Sonsini Advises Radar Therapeutics on IP Matters Related to $13.4 Million Seed Funding
On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.